8-K: scPharmaceuticals Secures $75 Million Loan, Sells Revenue Rights, and Expands Heart Failure Indication

scPharmaceuticals Inc. has entered into a $75 million term loan facility, sold revenue participation rights for $50 million, and received FDA approval to expand the FUROSCIX indication to include NYHA Class IV heart failure patients.

Summary

• scPharmaceuticals Inc. has secured a $75 million term loan facility, consisting of a $50 million Tranche A loan funded immediately and a $25 million Tranche B loan available until March 31, 2026, subject to certain conditions.
• The company has also sold revenue participation rights to Perceptive Credit Holdings IV, LP for $50 million, entitling the purchaser to a tiered single-digit percentage of net sales of FUROSCIX.
• The term loan has a maturity date of August 9, 2029, with interest at one-month term SOFR plus 6.75%, subject to a 3.25% floor.
• The company will use the proceeds to repay existing debt, support FUROSCIX commercialization, and for general corporate purposes.
• The revenue participation agreement allows the purchaser to receive payments until they reach 200% of the purchase price, with potential reductions based on payment amounts by certain dates.
• The company also announced positive topline results from a pharmacokinetic study of SCP-111, a low-volume formulation of furosemide, showing 107.3% bioavailability compared to IV furosemide.
• The FDA has approved the expansion of the FUROSCIX indication to include patients with NYHA Class IV chronic heart failure.
• Preliminary Q2 2024 results estimate net revenue at $8.1 million, a 33% sequential increase, with a gross-to-net discount of 8% and 9,300 FUROSCIX doses filled.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant funding secured, a promising new formulation of furosemide, and an expanded market for FUROSCIX. However, the decrease in cash and the potential for default under the credit agreement temper the overall sentiment.

Positives

• The company has secured significant funding through a term loan and revenue participation agreement.
• The expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients opens up a larger market.
• The pharmacokinetic study of SCP-111 shows promising results for a new formulation of furosemide.
• The company is experiencing strong revenue growth and improved gross-to-net discounts.
• The company has successfully increased the number of FUROSCIX doses filled.

Negatives

• The company will incur a prepayment penalty, exit fee, and accrued interest of approximately $54.2 million to terminate its existing credit facility.
• Cash and cash equivalents are expected to decrease from $58.4 million to $38.5 million in Q2 2024.
• Total operating expenses are expected to increase slightly from $22.0 million to $22.5 million in Q2 2024.

Risks

• The company is subject to financial covenants, including maintaining a minimum cash balance of $5 million and meeting minimum quarterly net sales targets.
• The company faces potential events of default under the credit agreement, including failure to make payments, breach of covenants, material adverse changes, and legal proceedings.
• The company is subject to a yield protection premium if it prepays the term loan before August 9, 2027.
• The company is subject to a revenue participation agreement that could limit future revenue potential.
• The company is subject to the risk of adverse regulatory events that could impact its ability to commercialize its products.

Future Outlook

The company will use the proceeds of the term loan to support the commercialization of FUROSCIX and for general corporate purposes. The company expects its closing procedures for the quarter ended June 30, 2024 to be completed on or about August 14, 2024.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

The announcement reflects a trend in the pharmaceutical industry where companies seek to secure funding through various means, including debt financing and the sale of future revenue streams. The expansion of the FUROSCIX indication is a positive development in the heart failure treatment market, where there is a need for effective therapies for patients with advanced heart failure.

Comparison to Industry Standards

• The $75 million term loan is a significant financing event for a company of scPharmaceuticals size, and is comparable to other similar financings in the biotech sector.
• The sale of revenue participation rights is a common strategy for biotech companies to raise capital, but the specific terms of the agreement, such as the tiered percentage and the 200% cap, are unique to this transaction.
• The 107.3% bioavailability of SCP-111 is a positive result compared to IV furosemide, and is comparable to other subcutaneous formulations of similar drugs.
• The expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients is a significant market expansion, and is comparable to other label expansions in the pharmaceutical industry.
• The 33% sequential increase in net revenue is a strong performance, and is comparable to other companies in the commercialization phase of their product lifecycle.

Stakeholder Impact

• Shareholders will benefit from the increased funding and potential for revenue growth.
• Employees will benefit from the continued commercialization of FUROSCIX and the development of new products.
• Customers will benefit from the expanded availability of FUROSCIX for patients with advanced heart failure.
• Creditors will benefit from the repayment of existing debt and the security of the new term loan.
• Suppliers will benefit from the continued demand for FUROSCIX and related products.

Next Steps

• The company will continue to commercialize FUROSCIX.
• The company will continue to develop SCP-111.
• The company will complete its financial closing procedures for the quarter ended June 30, 2024.

Key Dates

Keywords

scPharmaceuticals, FUROSCIX, term loan, revenue participation, heart failure, SCP-111, FDA approval, net sales, financial results, credit facility